Optimi Health Announces Appointment of New Director

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in public practice for 6 years. He currently serves as Senior Vice President and Partner at BFL Canada and has over a decade of experience providing tailored risk management and insurance solutions to clients in various industries, including manufacturing, distribution and life sciences.

Mr. Mosberian replaces Mr. Jonathan Schintler on the Company's Board of Directors. Optimi is thankful to Mr. Schintler for his time and contributions to the Company and wishes him the best on his next endeavor. Mr. Mosberian's appointment is subject to the approval of the Canadian Securities Exchange.

For more information, please contact:Dane Stevens, CEOOptimi Health Corp.Telephone: (778) 761-4551investors@optimihealth.cawww.optimihealth.ca